The short answer
TB-500 is C38H68N10O14 at 889.0 Da: seven residues, net positively charged, highly water-soluble and conformationally flexible. It carries none of the residues that usually dictate peptide handling (no cysteine, no methionine, no aromatic).
Key facts
- Formula
- C38H68N10O14
- Molecular weight
- 889.0 Da
- PubChem CID
- 62707662
- Net charge
- Positive at physiological pH
- Basic residues
- Two lysines
- Acidic residues
- One glutamate
- Solubility
- Readily water-soluble
Charge and solubility
Two lysines against one glutamate gives a net positive charge at physiological pH. Combined with two threonine hydroxyls and a glutamine amide, and with no hydrophobic core to bury, the peptide is strongly hydrophilic and dissolves readily in aqueous buffer. Solubility is rarely the limiting factor with this compound.
Adsorption is the practical issue instead
Small, highly charged peptides adsorb to glass and plastic surfaces, and at low concentrations the fraction lost to the container can be significant. This is the physical loss mechanism most likely to matter here, rather than degradation, which the composition largely rules out. Low-binding tubes and avoiding unnecessary transfers address it.
Research material referenced
TB-500 5mg, third-party HPLC tested
Flexibility
Seven residues with no proline and no disulfide constraint is about as unstructured as a peptide gets. It samples many conformations in solution, which has two consequences: no defined structure to solve, and an entropic penalty on binding that a constrained peptide would not pay.
The absent residues
No cysteine means no disulfide bonds and no reducing agent required. No methionine means no thioether oxidation and no +16 Da satellite on a mass spectrum. No asparagine means no deamidation at the usual hotspot. Between them these account for most peptide degradation in practice, and TB-500 is subject to none of them.
No spectroscopic handle
The absence of tryptophan, tyrosine and phenylalanine means almost no absorbance near 280 nm. The standard spectrophotometric method for peptide quantification does not work, and concentration must be established gravimetrically or by another analytical route. This is a real inconvenience rather than a trivial one.
How it compares within the library
TB-500 shares its no-cysteine, no-methionine, no-aromatic profile with Selank, and for the same practical reasons: chemically robust, physically prone to adsorption, and awkward to quantify. Semax and MOTS-c sit at the other end, carrying methionines that dominate their handling.
Quick reference
| Property | Value |
|---|---|
| Sequence | Ac-LKKTETQ |
| Molecular weight | 889.0 Da |
| Formula | C38H68N10O14 |
| PubChem CID | 62707662 |
| Cysteine | None |
| Methionine | None |
| Aromatic residues | None |
Frequently asked questions
Is TB-500 hard to dissolve?
No. It is small, highly charged and strongly hydrophilic. Adsorption to container surfaces is the more likely practical problem.
Does it need a reducing agent?
No. There is no cysteine in the sequence.
How is concentration measured without aromatic residues?
Not by 280 nm absorbance. Gravimetric preparation from a certified peptide content, or another analytical method, is required.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubChemPubChem · TB-500 (CID 62707662)pubchem.ncbi.nlm.nih.gov
- PubChemPubChem · LKKTETQ (CID 10169788)pubchem.ncbi.nlm.nih.gov
- PubMedGoldstein AL et al., Thymosin β4: a multi-functional regenerative peptide. Expert Opin Biol Ther 2012 (PMID 22074294)pubmed.ncbi.nlm.nih.gov
- PubMedShrivastava S et al., Thymosin beta4 and cardiac repair. Ann N Y Acad Sci 2010 (PMID 20536454)pubmed.ncbi.nlm.nih.gov
- PubMedSosne G et al., Thymosin beta 4 promotes corneal wound healing. Exp Eye Res 2002 (PMID 11950239)pubmed.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov · Thymosin β4 (RGN-259) dry eye Phase 3 (NCT03925727)clinicaltrials.gov
- PubChemPubChem · Thymosin β4 (CID 16132341)pubchem.ncbi.nlm.nih.gov
- GuidelineGoogle: Creating helpful, reliable, people-first contentdevelopers.google.com
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More TB-500 (Thymosin β4 fragment) articles
- TB-500 Storage, Stability and ReconstitutionNo cysteine, methionine or asparagine, so the usual degradation routes do not apply. Adsorption to surfaces is the loss mechanism that actually matters.
- TB-500 Half-Life and ClearanceA seven-residue peptide with no half-life extension carries no protection against renal filtration or peptidases. Why acetylation helps only at one end.
- Cell Migration: What the Studies ReportMigration requires continual actin remodelling, which gives a sequestering protein a plausible route to affect it. What the assays measure and what they do not.
- Angiogenesis: What the Literature ReportsNew vessel formation requires endothelial cells to migrate, which connects it to actin biology. What the models show and why the mechanism is less direct here.
- TB-500 Benefits: What Is Established and What Is NotActin sequestration, migration, angiogenesis, corneal and cardiac repair models. Sorted by how well each is established and which compound was actually used.